Nektar Therapeutics (NKTR) Return on Invested Capital (2011 - 2020)

Nektar Therapeutics' Return on Invested Capital history runs 7 years deep, the most recent figure standing at 0.01% for Q4 2020.

• On a quarterly basis, Return on Invested Capital changed N/A year-over-year to 0.01% in Q4 2020; TTM through Dec 2020 was 0.01%, a N/A change from a year earlier, with the FY2016 full-year figure at 0.21%, changed N/A from the prior year.
• Return on Invested Capital slipped to 0.01% in Q4 2020 per NKTR's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 1.89% in Q2 2018 and bottomed at 0.1% in Q1 2018.
• The 4-year median for Return on Invested Capital is 0.03% (2016), against an average of 0.1%.
• Across the five-year window, Return on Invested Capital slipped 7 bps in 2016 and surged 198 bps in 2018, its largest moves.
• Year by year, Return on Invested Capital stood at 0.05% in 2016, then climbed by 7 bps to 0.04% in 2017, then jumped by 4468 bps to 1.89% in 2018, then slumped by 101 bps to 0.01% in 2020.
• Per Business Quant, the three latest NKTR Return on Invested Capital figures stand at 0.01% (Q4 2020), 0.01% (Q3 2020), and 0.01% (Q2 2020).